Drugmakers Face Opposition on Chiefs' Pay by U.K. Advisory Firm

  • Shire's Ornskov paid 1,285 percent of salary in variable pay
  • Soriot's pay is 64 times that of average employee; Witty's 56

A key shareholder advisory firm recommended investors vote against the compensation awarded to chief executive officers at Shire Plc, AstraZeneca Plc and GlaxoSmithKline Plc, calling their incentive payments “excessive.”

To continue reading this article you must be a Bloomberg Professional Service Subscriber.